Expertise in
11
conditions

Dr. Mark R. Gilbert

Infectious Disease
Infectious Diseases Medical Associates LLC
1503 Lansdowne Ave Ste 3010, 
Darby, PA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
11
conditions
Infectious Diseases Medical Associates LLC
1503 Lansdowne Ave Ste 3010, 
Darby, PA 

Overview

Mark Gilbert is an Infectious Disease provider practicing medicine in Darby, Pennsylvania.

Dr. Gilbert is highly rated in 11 conditions, according to our data. His clinical expertise encompasses COVID-19, Pneumonia, Strep Throat, and Lymphangitis.

He is actively involved in clinical research, co-authoring 396 peer reviewed articles and participating in 10 clinical trials.

Specialties

Infectious Disease

Licenses

Internal Medicine in PA

Hospital Affiliations

Riddle Memorial Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Independent Health
  • EPO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

Infectious Diseases Medical Associates LLC
1503 Lansdowne Ave Ste 3010, Darby, PA 19023

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Enrollment Status: Recruiting
Publish Date: December 18, 2025
Intervention Type: Drug
Study Drug: ONC206
Study Phase: Phase 1
Evaluation of the Natural History of and Specimen Banking for Patients With Tumors of the Central Nervous System
Evaluation of the Natural History of and Specimen Banking for Patients With Tumors of the Central Nervous System
Enrollment Status: Completed
Publish Date: August 28, 2026
Intervention Type: Other
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers
Enrollment Status: Terminated
Publish Date: August 18, 2026
Intervention Type: Diagnostic test, Other, Drug
Study Drug: Nivolumab
Study Phase: Phase 2
Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Enrollment Status: Completed
Publish Date: April 17, 2026
Intervention Type: Drug
Study Drugs: TMZ, Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase II Trial of Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A)Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
A Phase II Trial of Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A)Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
Enrollment Status: Completed
Publish Date: August 11, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double Blind Phase II Trial of Surgery, Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
A Randomized, Double Blind Phase II Trial of Surgery, Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Enrollment Status: Terminated
Publish Date: August 08, 2025
Intervention Type: Other, Drug, Biological, Procedure
Study Drugs: Pembrolizumab, Temozolomide, Heat Shock Protein Peptide Complex-96 Vaccine
Study Phase: Phase 2
Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial
Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial
Enrollment Status: Completed
Publish Date: August 05, 2025
Intervention Type: Drug
Study Drugs: Carboplatin, Bevacizumab
Study Phase: Phase 2
Phase II Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
Phase II Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: November 22, 2023
Intervention Type: Drug
Study Drug: LB-100
Study Phase: Phase 2
Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed Glioblastoma
Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Biological, Other, Drug
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 1
View 8 Less Clinical Trials

396 Total Publications

Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial.
Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial.
Journal: medRxiv : the preprint server for health sciences
Published: July 03, 2026
Similar Doctors
Expertise in
14
conditions
Dr. Emily A. Blumberg
Infectious Disease
Expertise in
14
conditions
Dr. Emily A. Blumberg
Infectious Disease
Referral may be required
Before you request

MacGregor Infection Medicine And Travel Program

3400 Civic Center Boulevard, South Pavilion, 4th Floor, 
Philadelphia, PA 
 (4.5 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Emily Blumberg is an Infectious Disease provider practicing medicine in Philadelphia, Pennsylvania. Dr. Blumberg is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Cytomegalovirus Infection, Cytomegalic Inclusion Disease, HIV/AIDS, and Hepatitis C. Dr. Blumberg is board certified in Internal Medicine, 1984. Dr. Blumberg is currently accepting new patients.

Expertise in
13
conditions
Dr. Pablo M. Tebas
Infectious Disease
Expertise in
13
conditions
Dr. Pablo M. Tebas
Infectious Disease
Referral may be required
Before you request

MacGregor Infection Medicine And Travel Program

3400 Civic Center Boulevard, South Pavilion, 4th Floor, 
Philadelphia, PA 
 (4.5 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Pablo Tebas is an Infectious Disease provider practicing medicine in Philadelphia, Pennsylvania. Dr. Tebas is highly rated in 13 conditions, according to our data. His clinical expertise encompasses HIV/AIDS, Nontuberculous Mycobacterial Lung Disease, Myelitis, and AIDS Dementia Complex. Dr. Tebas is board certified in Infectious Disease, 2005 and Internal Medicine, 2004. Dr. Tebas is currently accepting new patients.

Expertise in
7
conditions
Dr. Michael Z. David
Infectious Disease
Expertise in
7
conditions
Dr. Michael Z. David
Infectious Disease
Referral may be required
Before you request

MacGregor Infection Medicine And Travel Program

3400 Civic Center Boulevard, South Pavilion, 4th Floor, 
Philadelphia, PA 
 (4.5 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael David is an Infectious Disease provider practicing medicine in Philadelphia, Pennsylvania. Dr. David is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Methicillin-Resistant Staphylococcus Aureus (MRSA), Sepsis, Osteomyelitis, Osteotomy, and Aneurysm Repair. Dr. David is board certified in Internal Medicine, 2004 and Infectious Disease, 2009. Dr. David is currently accepting new patients.

Frequently Asked Questions about Dr. Mark R. Gilbert

How do I make an appointment with Dr. Mark R. Gilbert?

You can book an appointment with Dr. Mark R. Gilbert by calling their office at 610-237-5817. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mark R. Gilbert a top-rated expert for COVID-19?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mark R. Gilbert is classified as an Distinguished expert for COVID-19, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mark R. Gilbert specialize in?

While Dr. Mark R. Gilbert is a Infectious Disease, they have specific expertise in COVID-19, Pneumonia, and Strep Throat. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Infectious Disease.

Does Dr. Mark R. Gilbert participate in research or clinical trials?

Yes. Dr. Mark R. Gilbert has published 396 articles and abstracts on conditions like COVID-19. You can view a list of Dr. Mark R. Gilbert's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mark R. Gilbert accept my insurance?

Dr. Mark R. Gilbert accepts most major insurance plans, including Aetna and Cigna. We recommend calling the office directly at 610-237-5817 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gilbert's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 25 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile